SRPT — Sarepta Therapeutics Share News
0.000.00%
Last trade - 00:00- $1.88bn
- $1.94bn
- $2.20bn
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Sarepta, Dyne fall after Novartis muscle disorder trial failure
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Sarepta, Dyne sink after Novartis muscle disorder trial failure
Trump picks White House adviser Heidi Overton to run FDA, source says (updated)
Sarepta Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Sarepta Q2 results beat expectations despite lower sales stemming from Elevidys relabel, unmet Roche milestone
Sarepta Therapeutics Inc expected to post earnings of 26 cents a share - Earnings Preview
Brief: Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
FDA advisers vote against Capricor's Duchenne heart disease therapy
U.S. STOCKS ON THE MOVE-Rocket Lab, silver miners, D-Wave Quantum
U.S. STOCKS ON THE MOVE-Rocket Lab, silver miners, D-Wave Quantum
Sarepta names former Abbvie president as CEO as Ingram retires
Sarepta gains after appointing former AbbVie executive Severino as CEO
Brief: Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
Brief: Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Sarepta Announces FDA Acceptance Of Sndas For Amondys 45® And Vyondys 53®